ATG GROUP
SOTIP ATG GROUP S.A.R.L operates in the aviation and aerospace industry. The company specializes in manufacturing, with a focus on precision industrial sheet metal work. It undertakes demanding projects in various sectors including aeronautics, railway, defense, and space. With a team of 99 employees, SOTIP ATG GROUP S.A.R.L is committed to delivering precision and quality in all its projects.
ATG GROUP
Industry:
Aerospace Industrial Manufacturing
Founded:
2002-01-01
Address:
Labège, Midi-Pyrenees, France
Country:
France
Website Url:
http://www.sotip.com
Total Employee:
51+
Status:
Active
Contact:
33 (0)5 61 00 19 90
Email Addresses:
[email protected]
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS OVH DNS
Similar Organizations
Anjou Aeronautique
ANJOU AERONAUTIQUE manufactures aeronautics products, offers aircraft safety solutions, cabin modifications, and design support.
Pierre PEZET SAS
PIERRE PEZET SAS manufactures complex parts for the aerospace industry, including cabin interiors and dashboards.
Toyo Matic Aerospace
Toyo Matic Aerospace Ltda manufactures components for the aviation and aerospace industry.
Official Site Inspections
http://www.sotip.com
- Host name: 109.234.162.100
- IP address: 109.234.162.100
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "ATG GROUP"
The Company - Sotio
The Company. SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. Our robust pipeline includes a next-generation PD-1-inhibiting cytokine, a proprietary technology designed …See details»
Sotio - Crunchbase Company Profile & Funding
Organization. Sotio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Sotio is an international biotechnology company leading the …See details»
Sotio - Wikipedia
SOTIO Biotech is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, North America, and Asia. The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), proprietary technology de…See details»
SOTIO Biotech - LinkedIn
SOTIO Biotech Biotechnology Research Prague 9, Czech Republic 8,855 followers Shaping the future of cancer immunotherapies by translating compelling science into patient benefit.See details»
Company split | SCTbio
On 1st July 2021, SOTIO a.s. was split into two separate entities SOTIO a.s. and SOTIO Biotech a.s. Technical operations & Manufacturing division remain under the name SOTIO a.s. The …See details»
Sotio Biotech AS - Drug pipelines, Patents, Clinical trials - Synapse
Patient enrollment and dosing ongoing in first-in-human study of BOXR1030 enhanced CAR T-cell therapy PRAGUE & BASEL, Switzerland & BOSTON--(BUSINESS WIRE)-- SOTIO Biotech, a …See details»
SOTIO Company Profile - Office Locations, Competitors, Revenue …
SOTIO has 5 employees across 5 locations and $300 k in total funding,. See insights on SOTIO including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Sotio - Funding, Financials, Valuation & Investors - Crunchbase
Sotio is a biotechnology company developing a new immunotherapy based on activated dendritic cells for the treatment of cancer. Search Crunchbase. ... How much funding has this …See details»
SOTIO Biotech AG – Swiss Biotech
SOTIO is a biotech company building a diverse portfolio of oncology products through its own R&D, collaborations, in-licensing, investments, M&A. SOTIO is conducting multiple Phase I to III clinical trials targeting various types of …See details»
Building A Broad Oncology Portfolio With SOTIO CEO …
Establishing an organization that can manage a diverse development pipeline for oncology therapies requires an equally diverse wealth of expertise. From in-house discovery to strategic licensing, the key capabilities required for research, …See details»
SOTIO Enters into Multi-Target Antibody Agreement with …
PRAGUE & BEIJING, July 16, 2024--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, and Biocytogen (HKEX: 02315), a global biotech company focused on …See details»
SOTIO, LLC becomes a member of Massachusetts Biotechnolog...
SOTIO, LLC is a biotechnology company developing a next generation Active Cellular Immunotherapy based on activated dendritic cells for the treatment of cancer and autoimmune …See details»
SOT201 - Drug Targets, Indications, Patents - Synapse
Dec 1, 2024 Originator Organization. Excoso as. Active Organization. Excoso as. Inactive Organization-Drug Highest Phase Phase 1. First Approval Date-Regulation-Login to view …See details»
SOTIO: First solid tumor patient dosed in Phase 1 clinical study
May 28, 2024 SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced the dosing of the first patient in its Phase 1, first-in-human clinical …See details»
SOTIP Group Company Profile 2024: Valuation, Investors
Information on acquisition, funding, investors, and executives for SOTIP Group. Use the PitchBook Platform to explore the full profile.See details»
ADC Technology | Sotio
SOTIO has four ongoing partnerships for the development of its ADC pipeline. It is developing two ADCs in partnership with NBE-Therapeutics (NBE) based on NBE’s proprietary site-specific …See details»
SOTIO Bolsters Leadership Team with Appointment of Martin...
Sep 14, 2022 SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced the appointment of Martin Steegmaier, Ph.D., MBA, as chief scientific officer. …See details»
metabolism and improved antitumor activity - bioRxiv
Nov 17, 2021 Therapeutics and/or SOTIO, LLC. Chimeric Antigen Receptor Constructs and Virus Production The GPC3 CAR construct (CAR) utilized is composed of a humanized anti …See details»
SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of ...
Jan 19, 2023 SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial …See details»